Recommended COVID-19 resources

For complete information from Wayne State University, including campus restart plans, training, messages from central units and more, visit the WSU coronavirus website

The following are reliable sources of information on COVID-19 recommended by the Wayne State Eugene Applebaum College of Pharmacy and Health Sciences Faculty Against Coronavirus Team (FACT).

Jump to general resources

Weekly links

A roundup of notable COVID-19 news and information curated by FACT

June 26, 2020

Hospitalization and Mortality among Black Patients and White Patients with COVID-19

Perspective: COVID-19 and the Need for Health Care Reform
"Never before has the interdependence of all our health, finances, and social fabric been so starkly visible."

Audio Interview: The Challenges of Safe Reopening, New England J. Med. [17:33]

Challenges of "Return to Work" in an Ongoing Pandemic

On Dexamethasone:

June 19, 2020

Dr. Michael Rybak interviewed by the Detroit News on the use of hydroxychloroquine for COVID-19

Clinical Characteristics and Morbidity Associated with Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit

Pandemic vaccines are about to face the real test

Press Release: Low-cost dexamethasone reduces death by up to one third in hospitalized patients with severe respiratory complications of COVID-19. Deaths were reduced by one-third in ventilated patients, and by one fifth in other patients receiving oxygen only. There was no benefit among those patients who did not require respiratory support. This study has yet to be peer-reviewed and published.
How deadly is the coronavirus? Scientists are close to an answer. Public health researchers use the infection fatality rate to gauge how to respond to a new disease, but it's tricky to calculate.

Why children avoid the worst coronavirus complications might lie in their arteries. Evidence is mounting that healthy blood vessels protect children from serious effects of COVID-19, such as stroke.
Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

Can phone apps slow the spread of the coronavirus?

U.S. academic research funding stays healthy despite pandemic

June 12, 2020

New Analysis Shows Governor Whitmer's Aggressive Action Against COVID-19 Saved Lives, Significantly Lowered Cases, Deaths [Also see Imperial College COVID-19 Response Team link below]

NIH COVID-19 Guidelines Updated
The National Institutes of Health (NIH) Coronavirus Disease 2019 (COVID-19) Treatment Guidelines issued an update June 11, 2020, available at Revisions include new recommendations on the use of remedesivir, hydroxychloroquine, and immune-based therapies, as well as new sections on pediatrics and SARS-CoV-2 testing. This is the second update of the NIH COVID-19 guidelines since they were first posted on April 21, 2020. WSU Applebaum Clinical Professor of Pharmacy Practice Susan Davis is a member of the NIH COVID-19 Guideline Panel. 

State-level tracking of COVID-19 in the United States by the Imperial College COVID-19 Response Team
"Overall, we show that while all US states have substantially reduced their reproduction numbers, we find no evidence that any state is approaching herd immunity or that its epidemic is close to over."

COVID-19 and flu, a perfect storm [Science editorial]

Big studies dim hopes for hydroxychloroquine
Amid politicization and scandal, a disappointing scientific picture is emerging.

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Has COVID-19 subverted global health?

Zoonotic origins of human coronaviruses

The Chinese government has moved slowly to permanently stop the sale and consumption of wild animals in the wake of the coronavirus epidemic, raising fears the practice may continue

First reported cases of SARS-CoV-2 infection in companion animals

Surviving the Surge: Evaluation of Early Impact of COVID-19 on Inpatient Pharmacy Services at a Community Teaching Hospital

June 5, 2020

COVID-19 and Racial Disparities

As of June 4, more than 1.9 million cases of COVID-19 have been reported in the United States, with over 109,000 known deaths. While the rate of new cases, hospitalizations, and deaths per day from COVID-19 has slowed in Michigan, we continue to feel the impact in our community and region particularly in some of our most vulnerable patients. 

Emerging data has identified that minority communities are disproportionately impacted by the pandemic, although race information is available in less than half of cases reported for national surveillance ( Factors that may contribute to this burden include a higher prevalence of comorbidities in patients from minority populations, as well as disparities in access to health, social, and economic resources.

Selected publications and preprints describing these disparities in COVID-19 include the following:

How You Should Read Coronavirus Studies, or Any Science Paper

The coronavirus outbreak could make it quicker and easier to trial drugs
Remote clinical trials and other changes could permanently alter pharmaceutical development: Part 7 in a series on science after the pandemic.

How to Discover Antiviral Drugs Quickly

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19  A Randomized Clinical Trial

Lancet, NEJM Retract Surgisphere Studies on COVID-19 Patients

Hydroxychloroquine for the Prevention of COVID-19 — Searching for Evidence

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for COVID-19

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe COVID-19

Remdesivir for 5 or 10 Days in Patients with Severe COVID-19

SARS-CoV-2 strategically mimics proteolytic activation 2 of human ENaC

May 29, 2020

Remdesivir for 5 or 10 days in patients with severe COVID-19

Hospitalization and mortality among black patients and white patients with COVID-19 [Louisiana]

Open letter to MR Mehra, SS Desai, F Ruschitzka, and AN Patel, authors of "Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis" published in The Lancet on May 22, 2020, and to journal editor Richard Horton with an international list of signatories

How countries are using genomics to help avoid a second coronavirus wave: Scientists in New Zealand, the United Kingdom and other places are using sequence data to track new infections as lockdowns ease

Ethical guidelines for COVID-19 tracing apps: Protect privacy, equality and fairness in digital contact tracing with these key questions

Reducing transmission of SARS-CoV-2: Countries that have been most effective in reducing the spread of COVID-19 have implemented universal masking, including Taiwan, Hong Kong, Singapore, and South Korea

May 22, 2020

FDA names 28 coronavirus antibody diagnostics it says should be taken off the market weeks after the agency closed its open-door policy on COVID-19 blood tests and required developers to submit their products and data for review

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Oxford COVID-19 vaccine to begin phase II/III human trials

Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform

Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: A multinational registry analysis

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in COVID-19
Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals

Advisory opinion 20-02 on the public readiness and emergency preparedness act and the secretary's declaration under the act - May 19, 2020

CDC: Considerations for Institutes of Higher Education

NHS contact tracing app: how does it work and when can you download it? [UK]

May 15, 2020

How coronavirus mutates and spreads

Coronavirus blood-clot mystery intensifies

Emergency approval of the antiviral drug remdesivir is the first good news of this pandemic. This is how Gilead Sciences prepared for the moment.

Roche's COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets accepting the CE mark

US approves first CRISPR coronavirus test that can be used at home

On decontaminating filtering facepiece respirators:

'Finally, a virus got me.' Scientist who fought Ebola and HIV reflects on facing death from COVID-19

CDC: Guidance for 'Opening up America Again' framework – Full 63-page document acquired by Associated Press

May 8, 2020

Remdesivir in the news

Antibody responses to COVID-19

Impact of COVID-19 on professional careers

May 1, 2020

April 24, 2020

April 17, 2020

April 10, 2020

April 3, 2020

General resources

The University of Minnesota Center for Infectious Disease Research and Policy is known for reliable information on infectious diseases/antibiotic resistance; their COVID-19 resource page aggregates interesting news and follows up with expert commentary.

The Society of Infectious Diseases Pharmacists offers a series of great educational videos and handouts giving a basic overview of experimental therapies being used for COVID-19. 

The American Society of Health-System Pharmacists offers an exhaustive list of tools, guidance documents and national pharmacy news related to COVID-19.

The Society for Healthcare Epidemiology of America provides some of the best resources on infection control, hand hygiene, occupational health and protective equipment.

The Infectious Diseases Society of America resource center provides links to resources on developments, guidelines, protocols, policies and tools for practitioners.

The Centers for Disease Control and Prevention (CDC) offers guidance for patients and health care professionals.

Who is at highest risk for COVID-19?  

The CDC's Morbidity and Mortality Weekly Report describes the epidemiology of the virus in the United States. Persons with certain underlying conditions appear to be at highest risk of severe COVID-19 associated disease. These include:

  • Diabetes mellitus
  • Chronic lung disease
  • Cardiovascular disease